Crossmark

Ebvallo® - die erste zugelassene allogene T-Zell-Therapie

Crossref DOI link: https://doi.org/10.1007/s15004-024-0694-y

Published Online: 2024-09-12

Published Print: 2024-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Springer, Günter
License Information

Text and Data Mining valid from 2024-09-01

Version of Record valid from 2024-09-01
More Information

Article History

First Online: 12 September 2024

Free to read: This content has been made available to all.